CG vs PODD Comparison

Carlyle Group is one of the world's largest alternative-asset managers, with $453 billion in total AUM, including $314 billion in fee-earning AUM, at the end of March 2025. The company has three core business segments: global private equity, which includes its private equity, real estate, infrastructure, and natural resources offerings (with $164 billion in total AUM and $99 billion in fee-earning AUM), global credit ($199 billion/$161 billion), and investment/fund solutions, known as Carlyle AlphInvest ($89 billion/$54 billion). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 3,100 active carry fund investors from 87 countries.

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.